"Working together we can secure the best use of scarce expertise and resources, maximising the health gain for all those with rare conditions" Alastair Kent OBE, Chair of RDUK

Latest Partners

Motor Neurone Disease Association

dsd families

UK Potsies

The Neuromuscular Centre

Children's Liver Disease Foundation

Pemphigus Vulgaris Network

 

You are here: Home / Governance

Governance

The Management Committee

Rare Disease UK is overseen by the Management Committee who meet monthly. The following people are members of the Management Committee:

  • Alastair Kent - Director of Genetic Alliance UK (RDUK Chair)
  • Steve Potter - Represents the Orphan Diseases Industry Group Partnership (RDUK Treasurer)
  • Becky Purvis - Policy and Public Affairs Manager - Association of Medical Research Charities (RDUK Secretary)
  • Dr Peter Corry - Paediatrician, Bradford
  • Mark Barrett - Chair of the Orphan Disease Industry Group
  • Dr Marita Pohlschmidt - Head of Research, Muscular Dystrophy Campaign
  • Laura Gilbert - Freelance Research Consultant
  • Dr Stephen Jolles - Clinical Immunologist, University of Wales Hospital Cardiff (Advisor for Wales)
  • Marie McGill - National Lead, Single Gene Complex Need Project (SGCN) (Advisor for Scotland)
  • Dr Fiona Stewart - Consultant in Medical Genetics, Belfast City Hospital (Advisor for Northern Ireland)

Genetic Alliance UK staff working on RDUK

  • Stephen Nutt (full-time) - Secretariat: Email:
  • Lauren Limb (full-time) - Research Assistant: Email:
  • Melissa Hillier (part-time) - Manager: Email:   
  • Buddug Williams (part-time) - RDUK in Wales: Email
  • Natalie Frankish (part-time) - RDUK in Scotland: Email:

Constitution

A copy of the RDUK constitution can be downloaded here.

Annual Reports

The RDUK Annual Report July 2009-June 2010 can be downloaded here

Minutes of AGM

The minutes of RDUK's 2010 Annual General Meeting can be downloaded here

Funding

RDUK is funded by an unrestricted educational grant from its pharmaceutical industry members.

Membership is either through the ABPI's Orphan Diseases Industry Group (ODIG) or through the Orphan Disease Industry Group Partnership (ODIGP) which includes non-ABPI companies.